ArticleScientific reports2025
Associations of serum CA 15-3 with interstitial lung disease, PM/Scl100 antibodies and other disease characteristics in systemic sclerosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate associations of serum CA 15-3 with interstitial lung disease (ILD), anti-PM/Scl100 antibodies, and other features in systemic sclerosis (SSc). We enrolled 59 SSc patients fulfilling 2013 ACR/EULAR criteria. CA 15-3 levels were compared between HRCT-confirmed ILD and non-ILD groups. Associations with autoantibodies, inflammation, patient-reported outcomes (PROs), and immunosuppressive therapy were assessed using nonparametric tests, ROC analysis, and multivariable logistic regression. Patients with ILD (n = 23) had significantly higher CA 15-3 levels (median 29.8 vs. 18.6 U/mL, p = 0.007). ROC analysis yielded an AUC of 0.72 (95% CI 0.62-0.81, p = 0.002). CA 15-3 remained independently associated with ILD (OR 1.05 per U/mL, 95% CI 1.01-1.10, p = 0.021). CA 15-3 was also higher in anti-PM/Scl100-positive patients (34.5 vs. 21.0 U/mL, p = 0.01). No associations were seen with other disease features, CRP, ESR, IL-6, or PROs. Serum CA 15-3 is independently associated with ILD in SSc and elevated in anti-PM/Scl100-positive patients. It may serve as an accessible biomarker of pulmonary involvement, pending validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.